|
|
|
|
||
Case study from the Gem/REO trial Thanks to Botinsel for finding this. The lead author is the PI for the new REO/Keytruda study. This patient was stage 4, KRAS mutant, with lung metastases. The prognosis would have been very poor. 26 months on REO before progressing is excellent. Who knows what adding Keytruda may have accomplished. ... CT and MRI scans revealed a 3.3 × 3.1 cm pancreatic head mass encasing superior mesenteric artery and vein with associated mesenteric periportal lymphadenopathy. He also had sub-centimeter lung nodules presumed to be metastatic deposits. He thus had a clinical stage 4 unresectable pancreatic cancer. Genomic analysis of tumor biopsies revealed the presence of KRAS mutation (G12D) and loss of CDKN2A/B. ... He completed 27 cycles of treatment with the last one in April 2014. At this time, he presented with disease progression with ascites and jaundice. |
return to message board, top of board |